FDA's New Rules for Cheaper Copycat Drugs: Biosimilars Get a Guidance Boost
Published Date: 9/9/2025
Notice
Summary
The FDA just released final advice to help drug makers prove their new protein medicines are just as good as the originals. This update affects companies developing biosimilars by clarifying how to compare products and what info to include in their applications. It aims to speed up approval and save money by making the process clearer and more reliable.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Clarifies how to show biosimilarity
The FDA released final guidance explaining how drug makers should design and evaluate comparative analytical studies to show a therapeutic protein is biosimilar to a reference product licensed under the Public Health Service Act. The guidance finalizes and replaces the draft guidance issued May 22, 2019 and the prior final guidance issued April 30, 2015.
Specifies CMC info for biosimilar applications
The final guidance provides recommendations to sponsors on the scientific and technical information to include in the chemistry, manufacturing, and controls (CMC) section of a marketing application submitted under the Public Health Service Act. Sponsors developing therapeutic protein biosimilars should follow these CMC recommendations when preparing their applications.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2025-17222 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Tobacco Product Establishment Registration and Listing
The FDA wants to keep track of tobacco product makers by updating their registration and listing rules. This affects businesses that make or sell tobacco products, who’ll need to share info with the FDA. The government is checking the paperwork to make sure it’s fair and won’t cost too much time or money.
Next: 2025-17228 — Cheniere Corpus Christi Pipeline, LP; Notice of Request for Extension of Time
Cheniere Corpus Christi Pipeline, LP is asking for more time—until the end of 2029—to finish building their Stage 3 Pipeline Project in Texas. This project includes a big pipeline and some powerful compressor machines to help move gas. The delay means they need extra time to complete important parts, but they’ve already started and even put some equipment to work.